Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ADH1B | P00325 | 1/20 | 0.30 |
| ▸ | ADH1C | P00326 | 1/20 | 0.30 |
| ▸ | ADH1A | P07327 | 1/20 | 0.30 |
| ▸ | ADH4 | P08319 | 1/20 | 0.30 |
| ▸ | ADH7 | P40394 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4450507 | 0.93 | TSHR (0.37) | TSHRALDH1A1ADH1BADH1CADH1A | |
| SCHEMBL3335779 | 0.91 | TSHR (0.41) | TSHRADH1BADH1CADH1AADH4 | |
| SCHEMBL27592030 | 0.91 | TSHR (0.41) | TSHRADH1BADH1CADH1AADH4 | |
| SCHEMBL6884225 | 0.91 | TSHR (0.41) | TSHRADH1BADH1CADH1AADH4 | |
| SCHEMBL56365 | 0.84 | — | — | |
| SCHEMBL3337621 | 0.83 | TSHR (0.35) | TSHRALDH1A1ADH1BADH1CADH1A | |
| SCHEMBL308118 | 0.83 | TSHR (0.39) | TSHRALDH1A1ADH1BADH1CADH1A | |
| SCHEMBL7003138 | 0.81 | LMNA (0.39) | — | |
| SCHEMBL27637092 | 0.81 | TSHR (0.42) | TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL3919347 | 0.81 | TSHR (0.39) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838889-A2 | LICHESTERINIC ACID AND THE DERIVATIVES OF SAME AS PIGMENTATION INHIBITORS | Centre National de la Recherche Scientifique (CNRS) (FR) | 2015-02-25 | — | — | EP | claimed |
| CN-104302632-A | Lichenin and derivatives thereof as pigmentation inhibitors | CENTRE NAT RECH SCIENT | 2015-01-21 | — | — | CN | claimed |
| WO-2013156738-A2 | LICHESTERINIC ACID AND THE DERIVATIVES OF SAME AS PIGMENTATION INHIBITORS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2013-10-24 | — | — | WO | claimed |
| CN-105755480-B | Efficient acidic cleaner | 江苏筑磊电子科技有限公司 | 2018-06-19 | — | — | CN | disclosed |
| CN-108048653-A | Improved metal solvent extracts reagent and application thereof | 考格尼斯知识产权管理有限责任公司 | 2018-05-18 | — | — | CN | disclosed |
| CN-105506283-B | Improved metal solvent extracts reagent and application thereof | 考格尼斯知识产权管理有限责任公司 | 2018-02-06 | — | — | CN | disclosed |
| EP-2838889-A2 | LICHESTERINIC ACID AND THE DERIVATIVES OF SAME AS PIGMENTATION INHIBITORS | Centre National de la Recherche Scientifique (CNRS) (FR) | 2015-02-25 | — | — | EP | disclosed |
| CN-104302632-A | Lichenin and derivatives thereof as pigmentation inhibitors | CENTRE NAT RECH SCIENT | 2015-01-21 | — | — | CN | disclosed |
| WO-2013156738-A2 | LICHESTERINIC ACID AND THE DERIVATIVES OF SAME AS PIGMENTATION INHIBITORS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2013-10-24 | — | — | WO | disclosed |
| US-20100143273-A1 | COSMETIC COMPOSITION COMPRISING AT LEAST ONE APROTIC HYDROCARBON-BASED VOLATILE SOLVENT | L'OREAL S.A. (FR) | 2010-06-10 | — | — | US | disclosed |
| EP-2083789-A1 | COSMETIC COMPOSITION COMPRISING AT LEAST ONE APROTIC HYDROCARBON-BASED VOLATILE SOLVENT | L'Oréal (FR) | 2009-08-05 | — | — | EP | disclosed |
| US-6420396-B1 | TREATMENT OF CANCER, ARTERIOSCLEROSIS, RESTENOSIS, OSTEOLYTIC DISORDERS, OPHTHALMIC DISORDERS, AND THEIR USE AS INTEGRIN ANTAGONISTS. INHIBITING ANGIOGENESIS | BEIERSDORF AG (DE) | 2002-07-16 | — | — | US | disclosed |
| US-20020016461-A1 | Biphenyl and biphenyl-analogous compounds as integrin antagonists | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-02-07 | — | — | US | disclosed |
| EP-1140809-A1 | NEW BIPHENYL AND BIPHENYL-ANALOGOUS COMPOUNDS AS INTEGRIN ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2001-10-10 | — | — | EP | disclosed |
| US-6162571-A | PHOTOCONDUCTIVE IMAGING MEMBER COMPRISED OF AN UNSYMMETRICAL PERYLENE; PHOTOACTIVE COMPONENT IN PHOTOCONDUCTIVE IMAGING MEMBERS USEFUL IN ELECTROPHOTOGRAPHIC PRINTING; ORGANIC SOLAR CELLS | XEROX CORPORATION (US) | 2000-12-19 | — | — | US | disclosed |
| WO-2000035864-A1 | NEW BIPHENYL AND BIPHENYL-ANALOGOUS COMPOUNDS AS INTEGRIN ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-06-22 | — | — | WO | disclosed |
| EP-0152765-A2 | Disozo dyestuffs, process for their preparation and their use | CASSELLA Aktiengesellschaft (DE) | 1985-08-28 | — | — | EP | disclosed |
| EP-0033928-B1 | USE OF ALKYL-SUBSTITUTED 1,3-DIOXOLANES AS PERFUMES, AND PERFUME COMPOSITIONS CONTAINING THEM | Henkel Kommanditgesellschaft auf Aktien (DE) | 1985-05-08 | — | — | EP | disclosed |
| US-4435315-A | COSMETICS, DETERGENTS | HENKEL KOMMANDITGESELLSCHAFT AUF ATKIEN (DE) | 1984-03-06 | — | — | US | disclosed |
| EP-0033928-A2 | Use of alkyl-substituted 1,3-dioxolanes as perfumes, and perfume compositions containing them | Henkel Kommanditgesellschaft auf Aktien (DE) | 1981-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016461-A1 | Biphenyl and biphenyl-analogous compounds as integrin antagonists | ITGB1, ITGB2, ITGB3 | TSHR 377/4885ALDH1A1 635/4885ADH1B 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.